The acquisition will cost around $2 billion at $21 per share, with an additional $400 million to be paid to Fusion if the biotech firm satisfies specific requirements.
This move is part of AstraZeneca’s cancer treatment pipeline expansion, as Fusion is focused on next-generation radioconjugates that kill cancer cells more accurately than chemotherapy, reducing risk for healthy cells.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.